Matsuno Osamu, Minamoto Seijiro
Department of Medicine for Allergic Disease, Osaka Habikino Medical Center, Habikino, JPN.
Cureus. 2021 Dec 23;13(12):e20644. doi: 10.7759/cureus.20644. eCollection 2021 Dec.
Patients with coronavirus disease 2019 (COVID-19) can develop eosinopenia. Eosinophils have various functions, including immunoregulation and antiviral activity, in addition to modulation of an inflammatory reaction. Benralizumab is an anti-interleukin-5Rα monoclonal antibody that selectively depletes eosinophils through enhanced antibody-dependent cell-mediated cytotoxicity. Whether eosinophil depletion affects COVID-19 prognosis is yet to be elucidated. Here, we present a case of a 60-year-old patient with severe asthma on benralizumab therapy, who tested positive for an acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The patient experienced an asymptomatic COVID-19 course without deterioration of asthma control. Eosinophil depletion did not contribute to a deterioration of the clinical status. Comorbidities play a major role in the severity of COVID-19 in patients with asthma. The findings of our case and a literature review revealed that benralizumab therapy is not associated with a significant negative impact on the disease course in COVID-19 patients.
2019冠状病毒病（COVID-19）患者可出现嗜酸性粒细胞减少。嗜酸性粒细胞具有多种功能，除了调节炎症反应外，还包括免疫调节和抗病毒活性。贝那利珠单抗是一种抗白细胞介素-5Rα单克隆抗体，可通过增强抗体依赖性细胞介导的细胞毒性选择性地消耗嗜酸性粒细胞。嗜酸性粒细胞减少是否会影响COVID-19的预后尚待阐明。在此，我们报告一例60岁接受贝那利珠单抗治疗的重度哮喘患者，其急性呼吸综合征冠状病毒2（SARS-CoV-2）感染检测呈阳性。该患者经历了无症状的COVID-19病程，哮喘控制未恶化。嗜酸性粒细胞减少并未导致临床状况恶化。合并症在哮喘患者COVID-19的严重程度中起主要作用。我们的病例及文献综述结果显示，贝那利珠单抗治疗对COVID-19患者的病程无显著负面影响。
